• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Viramune (nevirapine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Viramune (nevirapine)

  • Profile

Profile

Contact Information

Contact: Boehringer Ingelheim
Website: https://www.boehringer-ingelheim.com/products/viramune

Currently Enrolling Trials

    Show More

    General Information

    Viramune (nevirapine) is an antiretroviral drug.

    Viramune is specifically indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 15 days and older.

    Viramune is supplied as tablets and an oral suspension. The recommended dosing is as follows:

    Adults:

    The recommended dose for Viramune is one 200 mg tablet daily for the first 14 days, followed by one 200 mg tablet twice daily, in combination with other antiretroviral agents. The 14-day lead-in period with Viramune 200 mg daily dosing must be strictly followed as the lead-in period has been observed to decrease the incidence of rash. If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point, an alternative regimen should be sought. For concomitantly administered antiretroviral therapy, the manufacturer’s recommended dosage and monitoring should be followed.

    Pediatric Patients:

    The recommended oral dose for pediatric patients 15 days and older is 150 mg/m2 once daily for 14 days followed by 150 mg/m2 twice daily thereafter. The total daily dose should not exceed 400 mg for any patient.

    Mechanism of Action

    Viramune is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has a different mechanism of action and a distinct side effect profile from other classes of currently approved antiretrovirals. While the nucleoside analogues prevent the growth of the DNA chain, non-nucleoside drugs directly inactivate the enzyme.

    Side Effects

    The most common adverse effect associated with the use of Viramune is rash.

    The Viramune drug label comes with the following Black Box Warning: Fatal and non-fatal hepatotoxicity have been reported in patients taking Viramune. Discontinue immediately if clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms occur. Do not restart Viramune after recovery. Fatal and non-fatal skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions, have been reported. Discontinue immediately if severe skin reactions, hypersensitivity reactions, or any rash with systemic symptoms occur. Check transaminase levels immediately for all patients who develop a rash in the first 18 weeks of treatment. Do not restart Viramune after recovery. Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events.

    Clinical Trial Results

    In the first major study presented, ACTG 241, a randomized, double blind, placebo-controlled trial, researchers followed 398 subjects for 48 weeks at 16 participating investigational sites. All subjects entering the study had advanced HIV infection with CD4 cell counts of less than or equal to 350 (mean CD4 cell count for these patients was 153). The study compared the combination of AZT, ddI, and viramune to the combination of AZT, ddI, and placebo. Subjects in this trial had received extensive prior nucleoside therapy. The ACTG 241 study found that the combination of AZT, ddI, and viramune increased CD4 cell count significantly more than AZT, ddI, and placebo combination. In a substudy, viral markers were followed. In these subjects the combination of AZT, ddI, and viramune, reduced the viral load significantly more than AZT, ddI, and placebo, throughout the 48 weeks of the trial. The clinical significance of changes in viral RNA has not been established.

    The second major study presented, BI 1046, an international randomized, double blind, placebo-controlled trial, investigated viramune in previously untreated subjects. The six-month results from this twelve-month study compared the combinations of AZT, ddI, and viramune; AZTand ddI; and viramune and AZT in 151 HIV-1 infected subjects with CD4 counts between 200 and 600. Changes in CD4 counts through 28 weeks: levels of CD4 in those randomized to AZT plus ddI plus viramune, and AZT plus ddI remained significantly above baseline; however there was no significant difference between these arms. The triple drug regimen containing viramune decreased the viral load below the limit of detection in about two-thirds of the subjects, which was significantly greater than either double therapy regimen.

    Approval Date: 1996-06-01
    Company Name: Boehringer Ingelheim
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing